Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

7.460 -0.010 (-0.13%)
Official Closing Price Updated: 4:10 PM EDT, Jul 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Cybin Inc. Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Cybin And Fluence Partner To Support EMBARK Training For Phase 3 CYB003 Trial For Depression
Clinical-stage psychedelics biotech Cybin Inc. 
Via Benzinga
Depression Relief: Possible Therapy Boost With DMT & SSRIs, Per Small Pharma Clinical Results
New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of psychedelics and traditional pharma for the treatment of major depressive disorder (MDD) are out. 
Via Benzinga
Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More
Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge 
Via Benzinga
Topics Economy
Cybin Delivers Highest Dose Of Psilocybin Analog In Phase 2 For Major Depression
Clinical-stage psychedelics biotech Cybin (NYSE: CYBN) has completed enrollment in its Phase 2 study of novel deuterated psilocybin analog CYB003 for the potential treatment of Major Depressive... 
Via Benzinga
What 11 Analyst Ratings Have To Say About Cybin
Via Benzinga
6 Analysts Have This to Say About Cybin
Via Benzinga
Why Fresh Tracks Therapeutics Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares rose 70.2% to $0.8937 in pre-market trading after falling 10% on Tuesday. 
Via Benzinga
Why Elutia Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
Gainers Connexa Sports Technologies Inc. (NASDAQ: CNXA) shares rose 73.5% to $0.1313 in pre-market trading after falling 15% on Monday. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are a hot topic on Tuesday as investors seek out the latest news on the biggest traders this morning! 
Via InvestorPlace
Billionaire Steve Cohen Invests $19M In Cybin For Psychedelics R&D, Blake Mycoskie's $100M Pledge Update
Billionaire hedge fund and NY Mets owner, Steve Cohen amped up his support for psychedelics R&D through a new investment of nearly $19 million in beneficially owned shares of Cybin Inc. (NYSE: CYBN). 
Via Benzinga
The 3 Most Undervalued Under-$1 Stocks to Buy in September 2023
Cheap valuations and prospects for future growth should get individual investors excited for these under-$1 stocks to buy. 
Via InvestorPlace
NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years
NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035. 
Via Benzinga
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification 
Via Benzinga
Topics Artificial Intelligence
Cybin's Intellectual Powerhouse Grows With New US Patent Covering Deuterated 5-MeO-DMT
The U.S. Patent and Trademark Office (USPTO) has granted Canada-based psychedelics company Cybin Inc. (NYSE: CYBN) a new patent covering the composition of matter of deuterated 5-MeO-DMT analogs and... 
Via Benzinga
Topics Intellectual Property
Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety 
Via Benzinga
Mindset Pharma's $60M Acquisition, Otsuka's Leap Into Next-Gen Psychiatry Solutions
Canadian next-generation psychedelics developer Mindset Pharma (OTCMKTS: MSSTF) has entered into a definitive agreement to acquire all outstanding shares of Otsuka America Inc. the U.S. arm of Otsuka... 
Via Benzinga
Second Psychedelics Merger Of The Week? Silo Wellness To Buy Jamaica-Based Business For $31.9M
Silo Wellness (OTCQB: SILFF) has confirmed its intention to acquire all issued and outstanding securities of NUGL Inc./Kaya Group (OTC Pink: NUGL) in an arms-length transaction valued at $31.9... 
Via Benzinga
Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More
Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials 
Via Benzinga
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety
Psychedelics biotech Cybin (NYSE: CYBN) company and UK-based Small Pharma (OTCQB: DMTTF) announced their definitive arrangement agreement for Cybin’s acquisition of all Small Pharma’s issued and o 
Via Benzinga
Funding The Future Of Psychedelics: Cybin Launches Renewed ATM Equity Program Up To $35M
Psychedelics biotech Cybin Inc. (NYSE: CYBN) announced it has renewed its previously established at-the-market (ATM) equity program allowing the company to gradually issue and sell up to $35 million... 
Via Benzinga
Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports
Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds 
Via Benzinga
Topics Cannabis Economy
Psychedelics IP Protection: Cybin Nabs US Patent For Deuterated Analogs, Psilera Advances Next-Gen Library
Cybin’s New US Patent Covers Proprietary Deuterated Psychedelic Analogs 
Via Benzinga
Topics Intellectual Property
Cybin's Q1 2023 Financials, Deuterated Psychedelics Moving 'Steadily' Through The Clinic
Canadian clinical-stage psychedelics company Cybin (NYSE: CYBN) shared its unaudited financial results for the first quarter ended June 30, 2023: 
Via Benzinga
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published 
Via Benzinga
Cybin Closes Short-Lasting Overnight Public Offering With Top Issuance For $8.25M
Psychedelics biotech Cybin Inc. (NYSE: CYBN) closed its recently announced overnight marketed public offering with an aggregate of 24,264,706 units 
Via Benzinga
Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances... 
Via Benzinga
Why Aaron's Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) shares gained 188.8% to $4.13. The stock is now on the Regulation SHO "threshold security" list. 
Via Benzinga
Cybin Launches 3-Day Overnight Public Offering For Up To $8.25M, Suspends Prior Purchase Deal
Psychedelics company Cybin Inc. (NYSE: CYBN) announced an overnight marketed public offering of its units and confirmed its set pricing on an aggregate 24,264,706 Cybin units, at $0.34 each, for... 
Via Benzinga
US Stocks Mixed; Pfizer Earnings Beat Views
U.S. stocks were mixed this morning, with the Dow Jones trading slightly higher on Tuesday. Following the market opening Tuesday, the Dow traded up 0.03% to 35,568.68 while the NASDAQ fell 0.57% to... 
Via Benzinga
Why TETRA Technologies Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Gainers American Superconductor Corporation (NASDAQ: AMSC) shares surged 112.1% to $21.38 in pre-market trading. AMSC is expected to report first-quarter results on Aug. 9, 2023. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.